Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635 Press ReleaseRob MaguireMarch 25, 2024
Verge Genomics to Present at Evercore ISI 2024 Emerging Biotech Conference Press ReleaseRob MaguireFebruary 21, 2024
Getting the most out of digital endpoints: case studies from Verge’s CMO NewsRob MaguireFebruary 15, 2024
Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with VRG50635 Press ReleaseRob MaguireJanuary 9, 2024
Verge Genomics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024 Press ReleaseRob MaguireJanuary 3, 2024
Verge Genomics Will Use Modality.AI in Its ALS Phase 1b Clinical Trial of Its Lead Drug Candidate VRG50635 Press ReleaseRob MaguireNovember 29, 2023
Verge Genomics and the Pritzker Neuropsychiatric Disorders Research Consortium Form Cutting Edge Schizophrenia Research Collaboration Press ReleaseRob MaguireOctober 31, 2023
CMO Diego Cadavid to participate in panel discussion at Fierce Biotech Summit EventsRob MaguireOctober 13, 2023
Verge to share initial results from the Phase 1 trial of VRG50635 at the American Neurological Association Annual Meeting EventsRob MaguireSeptember 12, 2023
Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases Press ReleaseRob MaguireSeptember 8, 2023
The CEO of Verge Genomics shares how she's overcome gender and age biases in biotech by showing people 'there can be a new way of doing things' NewsRob MaguireAugust 18, 2023
The 30 young leaders who are forging a new future for the healthcare industry in 2023 NewsRob MaguireAugust 17, 2023
At ENCALS, Commitment to Understanding the Cause of ALS and developing effective Treatments Rob MaguireJuly 18, 2023
CMO Diego Cadavid, M.D. to present data for Phase 1 of VRG50635 at ENCALS 2023 EventsRob MaguireJuly 13, 2023
Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Press ReleaseRob MaguireJune 15, 2023
Verge Genomics to Present at Mass General Brigham & Bank of America World Medical Innovation Forum Press ReleaseRob MaguireJune 6, 2023
Verge Genomics to Incorporate Emerald Digital Health Technology into its ALS Phase 1b Proof-of-Concept Clinical Trial Press ReleaseRob MaguireMay 23, 2023
